2017 Fast Lane Honoree Avery Therapeutics
More than 26 million people worldwide suffer from heart failure and the number of cases is increasing at more than 13% per year. In the US, heart failure is the number one cause of hospital readmissions in patients over 65 and results in over $39 billion in treatment costs annually. The progression of heart failure results in a 50% mortality rate within 5 years of diagnosis. But what if it didn’t have to be like this? That is a question being addressed by the team at Avery Therapeutics, Inc. The startup company is based on the application of technology invented at the University of Arizona College of Medicine-Tucson and the Southern Arizona VA. In 2017, Avery Therapeutics licensed the beating heart graft technology from the University of Arizona. Pre-clinical studies have already shown that the technology, called MyCardia™, improves heart function.
Reshaping the Patient Experience (Panel)
Moderated by Jude LaCava, Co-founder, Dorothy Foundation;
Panelists: -Eric Greenman, MD, Founder
and Chief Medical Officer, iTel Companies; Marie
Wesslehoft, President & Co-founder, MSDx; Neel
Mehta, Co-founder and Chief Strategy Officer, EpiFinder Inc.
Bard Peripheral Vascular - 2017 Arizona Bioscience Company of the Year
Bard Peripheral Vascular specializes in the development of surgical and interventional devices for the treatment of diseases affecting the peripheral vascular system, which consists of veins and arteries in the arms, hands, legs, and feet. The peripheral arteries supply oxygenated blood to the body, and the peripheral veins lead deoxygenated blood from the capillaries in the extremities back to the heart.
AZBio Leadership Conversation with the Honorable James C. Greenwood (2014)
James C. Greenwood is President and CEO of the Biotechnology Industry Organization (BIO) in Washington, D.C., which represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Since his appointment in January of 2005, he has markedly enhanced the trade association’s capacity – increasing both its staff and budget by nearly fifty percent. BIO is now a world class advocacy organization playing a leading role in shaping public policy on a variety of fronts critical to the success of the biotechnology industry at the state and national levels as well as internationally.
Mr. Greenwood represented Pennsylvania’s Eighth District in the U.S. House of Representatives from January 1993 through January 2005. A senior member of the Energy and Commerce Committee, he was widely viewed as a leader on health care and the environment. From 2001 to 2004, Mr. Greenwood served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation with oversight authority over issues in the full Committee’s vast jurisdiction.
Clinical Trials in Arizona - CBR
Cord Blood Registry® (CBR®) is the world’s largest newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing samples from more than 500,000 children. CBR is dedicated to advancing the clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish FDA-regulated clinical trials for conditions that have no cure today Presenter: CeciliaFairley, Clincial Specialist at Cord Blood Registry